Peregrine Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CDMO)

$3.68 -0.23 (-5.88 %)
(As of 01/17/2018 04:00 PM ET)
Previous Close$3.68
Today's Range$3.66 - $3.90
52-Week Range$1.98 - $5.78
Volume191,080 shs
Average Volume227,374 shs
Market Capitalization$166.38 million
P/E Ratio-5.26
Dividend YieldN/A

About Peregrine Pharmaceuticals (NASDAQ:CDMO)

Peregrine Pharmaceuticals logoAvid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals


Debt-to-Equity RatioN/A
Current Ratio1.46%
Quick Ratio0.97%


Trailing P/E Ratio-5.25714285714286
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$57.63 million
Price / Sales2.89
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book2.92


Trailing EPS($0.70)
Net Income$-28,150,000.00
Net Margins-39.23%
Return on Equity-52.55%
Return on Assets-24.77%


Outstanding Shares45,210,000

Peregrine Pharmaceuticals (NASDAQ:CDMO) Frequently Asked Questions

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "CDMO."

When did Peregrine Pharmaceuticals' stock split? How did Peregrine Pharmaceuticals' stock split work?

Peregrine Pharmaceuticals shares reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Peregrine Pharmaceuticals stock prior to the reverse split would have 14 shares after the split.

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals (NASDAQ:CDMO) released its quarterly earnings results on Monday, December, 11th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.15. Peregrine Pharmaceuticals had a negative net margin of 39.23% and a negative return on equity of 52.55%. View Peregrine Pharmaceuticals' Earnings History.

When will Peregrine Pharmaceuticals make its next earnings announcement?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Peregrine Pharmaceuticals.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2018?

1 equities research analysts have issued twelve-month price objectives for Peregrine Pharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Peregrine Pharmaceuticals' share price to reach $10.00 in the next year. View Analyst Ratings for Peregrine Pharmaceuticals.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Roger J. Lias Ph.D., President, Chief Executive Officer
  • Paul J. Lytle, Chief Financial Officer (Age 48)
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary (Age 52)
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property (Age 50)
  • Joseph Carleone Ph.D., Director
  • Richard B. Hancock, Director
  • Joel McComb, Director
  • Gregory P. Sargen, Director
  • Mark R. Bamforth, Independent Director (Age 52)

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $3.68.

How big of a company is Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals has a market capitalization of $166.38 million and generates $57.63 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Peregrine Pharmaceuticals employs 323 workers across the globe.

How can I contact Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals' mailing address is 2642 Michelle Dr Ste 200, TUSTIN, CA 92780-7019, United States. The biopharmaceutical company can be reached via phone at +1-714-5086100 or via email at [email protected]

MarketBeat Community Rating for Peregrine Pharmaceuticals (CDMO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Peregrine Pharmaceuticals (NASDAQ:CDMO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$10.00$5.25
Price Target Upside: 136.97% upside129.89% upside221.54% upside720.31% upside

Peregrine Pharmaceuticals (NASDAQ:CDMO) Consensus Price Target History

Price Target History for Peregrine Pharmaceuticals (NASDAQ:CDMO)

Peregrine Pharmaceuticals (NASDAQ:CDMO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018Noble FinancialReiterated RatingBuyLowView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 1/17/2016 forward)


Peregrine Pharmaceuticals (NASDAQ:CDMO) Earnings History and Estimates Chart

Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:CDMO)

Peregrine Pharmaceuticals (NASDAQ CDMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/11/2017Q2 2018($0.12)($0.27)ViewN/AView Earnings Details
9/11/2017Q1 2018($0.12)($0.06)$15.22 million$27.08 millionViewN/AView Earnings Details
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
7/14/2011Q4 2011($1.12)($1.05)ViewN/AView Earnings Details
3/11/2011Q3 2011($0.91)($0.97)ViewN/AView Earnings Details
12/9/2010Q2 2011($0.84)($0.92)ViewN/AView Earnings Details
9/9/2010Q1 2011($0.70)($0.99)ViewN/AView Earnings Details
7/14/2010Q4 2010($0.70)($1.12)ViewN/AView Earnings Details
3/11/2010Q3 2010($0.22)ViewN/AView Earnings Details
12/10/2009Q2 2010($0.41)ViewN/AView Earnings Details
9/3/2009Q1 2010($0.35)ViewN/AView Earnings Details
7/14/2009Q4 2009($0.70)ViewN/AView Earnings Details
3/11/2009Q3 2009($0.35)($0.52)ViewN/AView Earnings Details
12/10/2008Q2 2009($0.70)($0.70)ViewN/AView Earnings Details
9/9/2008Q1 2009($0.77)ViewN/AView Earnings Details
7/14/2008Q4 2008($0.70)ViewN/AView Earnings Details
3/11/2008Q3 2008($0.94)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Peregrine Pharmaceuticals (NASDAQ:CDMO) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.57 EPS


Dividend History for Peregrine Pharmaceuticals (NASDAQ:CDMO)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ CDMO)

No insider trades for this company have been tracked by


Peregrine Pharmaceuticals (NASDAQ CDMO) News Headlines

Comparing Peregrine Pharmaceuticals (CDMO) & Cardiome Pharma (CRME)Comparing Peregrine Pharmaceuticals (CDMO) & Cardiome Pharma (CRME) - January 17 at 8:20 AM
Peregrine Pharmaceuticals (CDMO) and The Competition Head-To-Head ReviewPeregrine Pharmaceuticals (CDMO) and The Competition Head-To-Head Review - January 16 at 11:24 PM
Head to Head Review: Ocera Therapeutics (OCRX) versus Peregrine Pharmaceuticals (CDMO)Head to Head Review: Ocera Therapeutics (OCRX) versus Peregrine Pharmaceuticals (CDMO) - January 16 at 9:32 AM
Head to Head Review: Peregrine Pharmaceuticals (CDMO) and Its PeersHead to Head Review: Peregrine Pharmaceuticals (CDMO) and Its Peers - January 13 at 5:54 AM
Contrasting Peregrine Pharmaceuticals (CDMO) & Its CompetitorsContrasting Peregrine Pharmaceuticals (CDMO) & Its Competitors - January 12 at 9:06 PM
Head to Head Survey: Peregrine Pharmaceuticals (CDMO) vs. Its RivalsHead to Head Survey: Peregrine Pharmaceuticals (CDMO) vs. Its Rivals - January 12 at 5:34 PM

SEC Filings

Peregrine Pharmaceuticals (NASDAQ:CDMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Peregrine Pharmaceuticals (NASDAQ:CDMO) Income Statement, Balance Sheet and Cash Flow Statement


Peregrine Pharmaceuticals (NASDAQ CDMO) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.